VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE AMEX:CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2011 BIO CEO & Investor Conference hosted by the Biotechnology Industry Organization (BIO). The conference will take place February 14-15 at the Waldorf-Astoria in New York.
Mr. Kersten’s presentation will be on Tuesday, February 15th, at 9:30 a.m. The presentation will be webcast live with a slide presentation and archived until May 16, 2011. The webcast can be accessed at http://www.veracast.com/webcasts/bio/ceoinvestor2011/28204257.cfm.
About CEL-SCI Corporation
CEL-SCI Corporation is developing products that empower immune defenses. Its lead product, Multikine®, is currently being tested in a global Phase III clinical trial that started in December 2010. In Phase II clinical trials Multikine was shown to be safe and well-tolerated and to improve the patients' overall survival by 33 percent at a median of three and a half years following surgery.
CEL-SCI is also developing an immunotherapy (LEAPS-H1N1-DC) to treat H1N1 hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis using its LEAPS technology platform. The LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
CONTACT:
CEL-SCI Corporation
Gavin de Windt, 703-506-9460
www.cel-sci.com
KEYWORDS: United States North America New York Virginia
INDUSTRY KEYWORDS: Surgery Health Biotechnology Infectious Diseases Pharmaceutical General Health
MEDIA:
| Logo |